Sarah Kernaghan

Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial

Andrew Tutt, Holly Tovey, Maggie C.U. Cheang et al. · Nature Medicine · 2018 · 903 citations · Full text

Medicine, Oncology, Pharmacology +11

Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial

Nicholas C. Turner, Belinda Kingston, Lucy Kilburn et al. · The Lancet Oncology · 2020 · 352 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer

Nicholas C. Turner, Claire Swift, Ben Jenkins et al. · Annals of Oncology · 2022 · 191 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Abstract S3-01: The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or <i>BRCA1/2</i> breast cancer (CRUK/07/012)

Andrew Tutt, Lucy Kilburn, Cheryl Gilett et al. · Cancer Research · 2015 · 166 citations

Medicine, Oncology, Pharmacotherapy +17

Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial

Ian Judson, James P. Morden, Lucy Kilburn et al. · The Lancet Oncology · 2019 · 98 citations · Full text

Medicine, Oncology, Pharmacology +11